Clostridium Difficile Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients
Conditions: Clostridium Difficile Colonization; Clostridium Difficile Diarrhea Interventions: Drug: Vancomycin; Dietary Supplement: Culturelle; Drug: Vancomycin Placebo; Drug: Probiotic Placebo Sponsor: Hamilton Health Sciences Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2020 Category: Research Source Type: clinical trials
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection
WHITE PLAINS, N.Y., Jan. 15, 2020 /PRNewswire/ -- Acurx Pharmaceuticals, LLC ( " Acurx " or the " Company " ), a privately held, clinical stage biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 15, 2020 Category: Pharmaceuticals Source Type: clinical trials
